Anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody

Melanoma is often referred to as 'Australia's national cancer' as the country has the highest rate of melanoma in the world.¹ It is estimated that more than 13,000 new cases are diagnosed each year. ² Such high rates are due to the country's high levels of ultraviolet (UV) radiation combined with an 'outdoor' culture that includes high participation rates in sport, beach, and outdoor activities.

PRAME (PReferentially expressed Antigen in MElanoma) is a tumour biomarker expressed in most cutaneous and ocular melanomas as well as various other malignant neoplasms.³

Roche Anti-PRAME (EPR20330) has been included on the ARTG as a Class 3 IVD (ARTG 418288).

Different from other melanocytic markers such as Melan A and Sox10 that highlight all melanocytes in the initial diagnosis, PRAME preferentially highlights melanoma cells, which aids in distinguishing benign from malignant melanocytic lesions. In addition, in patients diagnosed with melanoma, PRAME can increase confidence in achieving clean surgical margins.

PRAME expression in formalin-fixed paraffin-embedded tissue, is detected by immunohistochemistry and frequently demonstrates a diffuse nuclear immunostaining pattern in in situ and invasive melanoma. In contrast, the majority of benign melanocytic nevi lack nuclear PRAME staining.⁴

Studies suggest that detection of PRAME expression by immunohistochemistry (IHC) may complement findings from routinely used H&E and other IHC panels and aid in:

• Differential diagnoses of benign versus malignant melanocytic lesions^3,4
• Evaluation of tumour margins in melanoma specimens ^3,4
• Evaluation of sentinel lymph nodes in melanoma cases.⁵

In summary, PRAME provides additional evidence for diagnostic interpretation of difficult cutaneous melanocytic tumors.